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Cancer is one of the leading causes of morbidity and mortality worldwide and it is 
expected to become the leading cause of death in the coming decades. Although 
major advances have been achieved in the eld of cancer treatment, multi-drug 
resistance (MDR) and relapse are still frequent. Initially, MDR was related only to 
eux transporters, drug kinetics and regulation of drug targets; however, more 
recent studies revealed that tumor heterogeneity is a major driver.
Current anticancer therapies mainly include chemotherapy, radiotherapy or surgery, 
and so far alone or in combination fail to eradicate MDR-cells, which ultimately leads 
to relapse. Nanotechnology oers a novel set of smart drug delivery systems with 
unique phsycochemical properties that enable to actively target MDR-cells and 
overcome drug resistance with combination therapy. 
• Present the burden of cancer therapy failure due to drug resistance.
• Analyse the main factors triggering drug resistance in conventional chemotherapy.
• Expose the novel alternative nanotechnology-based approaches and their key role 
in overcoming drug chemoresistance.
• Scientific literature searched using Pubmed and Scopus platforms, based on impact 
factor 6 or higher and published from 2005.
• Additional information was extracted from assitance to conferences, interviews 
with researchers, meeting reports or PhD thesis.
• Despite remarkable progress made in prevention, diagnosis and treatment, 
ecient cancer therapies remain elusive.
• The major causes that lead to treatment failure are: late stage diagnosis, and the 
lack of adequate approaches to treat metastases and tumor resistance.
• Tumor heterogeneity is the major trigger to cancer multi-drug resistance; where 
cancer stem cells play a major role in cancer initiation and progression, resistance, 
recurrence and metastases.
Combination therapy is usually dened as the use of two or more agents 
co-delivered simultaneously or a combination of dierent therapies. Since drugs 
dier in pharmacokinetic and pharmacodynamics properties, the target cells or 
tissues might not synchronously receive the optimal levels of each therapeutic 
agent if administrated systemically. However, the use of a nanocarrier to deliver 
them simultaneously allows for a better spatiotemporal control. These smart 
delivery systems enable to: (i) eﬀectively combine the main therapeutic agent with 
another molecule that can block any level of MDR, and (ii) target selectively CSC. 
Acting on the signalling pathways and the factors of the microenvironment that 
induce MDR makes possible to overcome either intrinsic CSC or acquired resistance 
and would signicantly improve the treatment outcome.
The Cancer Stem Cells (CSC) 
hypothesis assumes a hierarchial 
tumor organization, where only 
a small subset of cells has 
tumorigenic capacity and is the 
responsible to maintain tumor 
heterogeneity. CSC share some 
properties with normal stem 
cells, like intrinsic resistance, and 
they have also been related to 
tumor initiation, progression, 
metastases and relapse.
• Novel approaches based on nanotechnology provide great advances and oﬀer 
new perspective into early diagnosis, therapies and cancer resistance.
• Nanocarriers have unique features that signicantly improve drug delivery.
• Combinational nano-based therapies enable to overcome any level of drug 
resistance and eective targeting to cancer stem cells.
Many types of nanoparticles are 
suitable to be used as nanocarriers 
when they have been properly 
functionalized and made  
biocompatible to perform drug 
delivery, depicted in Figure 1.
These drug delivery systems can 
be tuned at the nano scale and 
rationally designed to achieve 
personalized features as: specific 
targeting, controlled release of the 
payload and co-delivery of two or 
more therapeutic agents, and 
theranostics.
Figure 1. Examples of some of the main classes of 
nanoparticles that can be used for drug delivery.
The use of nanovehicles in drug delivery provides a new approach that oﬀers 
solutions to some of the problems associated to the systemic delivery of the 
conventional chemotherapy. Nanocarriers can protect a drug from degradation by 
evading the reticuloendothelial system (RES) and, thus, a high blood circulation 
prole enables transport through biological barriers, increasing the availability of 
drug at the targeted site and reducing the toxicity and other side eects.
Figure 2. (Left) An example 
of a nanocarrier for 
co-delivery. (Right) MDR 
mechanisms and dierent 
approaches to overcome 
them using combination 
therapy in order to improve 
treatment outcome.
